LinkedIn Profile

Access Corcept Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:cort 112768 Apr 21st, 2024 12:00AM Corcept Therapeutics 30K 379.00 Open Apr 20th, 2024 11:15PM Apr 20th, 2024 11:15PM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 20th, 2024 12:00AM Corcept Therapeutics 30K 379.00 Open Apr 19th, 2024 11:12PM Apr 20th, 2024 04:48PM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 19th, 2024 12:00AM Corcept Therapeutics 30K 379.00 Open Apr 18th, 2024 11:19PM Apr 18th, 2024 11:19PM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 18th, 2024 12:00AM Corcept Therapeutics 30K 375.00 Open Apr 17th, 2024 11:18PM Apr 18th, 2024 06:08PM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 17th, 2024 12:00AM Corcept Therapeutics 29K 373.00 Open Apr 16th, 2024 11:09PM Apr 17th, 2024 02:32PM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 16th, 2024 12:00AM Corcept Therapeutics 29K 373.00 Open Apr 15th, 2024 11:05PM Apr 16th, 2024 10:48AM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 15th, 2024 12:00AM Corcept Therapeutics 29K 371.00 Open Apr 14th, 2024 11:01PM Apr 15th, 2024 04:29PM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 14th, 2024 12:00AM Corcept Therapeutics 29K 371.00 Open Apr 13th, 2024 10:50PM Apr 14th, 2024 10:48AM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 13th, 2024 12:00AM Corcept Therapeutics 29K 371.00 Open Apr 12th, 2024 10:41PM Apr 13th, 2024 11:16AM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services
nasdaq:cort 112768 Apr 12th, 2024 12:00AM Corcept Therapeutics 29K 371.00 Open Apr 11th, 2024 10:45PM Apr 12th, 2024 08:11AM At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept. Open Open 149 Commonwealth Dr Menlo Park CA US 94025 Corcept Therapeutics Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.